A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti- Retroviral Activity of MK-8583 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Patients
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2019
Price : $35 *
At a glance
- Drugs MK-8583 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 21 Mar 2019 Status changed from active, no longer recruiting to completed.
- 18 Mar 2019 Planned End Date changed from 5 Mar 2019 to 29 Mar 2019.
- 18 Mar 2019 Planned primary completion date changed from 5 Mar 2019 to 29 Mar 2019.